Tipifarnib and Osimertinib in EGFR-mutated Non-Small Cell Lung Cancer

Summary

This is a Phase 1a/b, multicenter, open-label, dose escalation (1a) and dose expansion (1b) study. The purpose of this study is to measure safety, tolerability, and preliminary efficacy with the combination of tipifarnib with osimertinib in patients with advanced/metastatic EGFR-mutated non-small cell lung cancer.

Timeline

Start

2023-02-01

Primary completion

2027-07-27

Completion

2027-07-27

Outcome

Outcome not reported

Stopped (Enrollment): “This study was withdrawn due to a strategic business decision; no patients were enrolled.”

Drugs

Indications